Cdc42-binding kinase

Cdc42-binding kinase, also known as myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK), belongs to the DMPK family. Cdc42-binding kinase is an effector protein of Cdc42 and Rac1, a multi-domain protein of about 190kDa. Cdc42-binding kinase contains an N-terminal kinase domain, an intermediate coiled-coil domain, and a C-terminal regulatory domain (including C1, PH, CNH domains, and CRIB motifs). Cdc42-binding kinase exists as a homodimer, and the coiled-coil domain is about 55 nm long, which acts as a "molecular ruler" to locate the distance between the kinase domain and the membrane[1][2].
There are three subtypes of MRCK in humans: α, β, and γ. α and β are widely expressed, and γ is mainly expressed in muscle tissue. All three contain CRIB motifs and can bind to Cdc42/Rac1. The γ subunit has a preference for TC10[1][2].
Cdc42-binding kinase promotes actomyosin contraction by phosphorylating myosin regulatory light chain (MLC2) Ser19 and inhibiting myosin phosphatase (MLCP) subunit MYPT1, and participates in the establishment of cell polarity, directional migration, neurite growth, epithelial cell apical contraction, and cancer cell invasion. It can also phosphorylate LIMK1 to stabilize actin fibers.
Mechanistically, Cdc42-binding kinase binds to activated Cdc42-GTP through the CRIB motif, binds to membrane lipids such as phosphatidylserine (PS) with the help of C1 and PH domains, and localizes to the cell membrane; the coiled-coil domain mediates dimerization and maintains the active conformation of the kinase, binds to the actomyosin complex through the adaptor protein LRAP25/35a, such as LRAP35a mediating the binding of MRCK to MYO18A, and regulating the dynamics of lamellipodia actin fibers. At the same time, Cdc42-binding kinase participates in the Cdc42 and Rac1 signaling pathways, and is recruited to specific membrane regions by binding to GTP-formed Cdc42/Rac1, synergistically regulating the reorganization of the actin skeleton[1][2].
Interacting proteins of Cdc42-binding kinase include small GTPases CDC42 and Rac1, membrane lipids such as PS, inositol bisphosphates (PIPs), adaptor proteins LRAP25/35a, Shroom (ROCK-like adaptor protein), and actin-related proteins MYO18A and LIMK1[1][2].
Among the inhibitors of Cdc42-binding kinase, BDP5290 (HY-12437) is a selective inhibitor of MRCK, which is more than 50 times more selective for MRCKβ than ROCK and can block cancer cell invasion; Chelerythrine (HY-N2359) inhibits the activity of MRCK by binding to its C1 domain, affecting the formation of sheet-like actin fibers, with an IC50 of 1.8 μM, but there is a non-target effect[1][2].
In summary, MRCK abnormalities may be closely related to cancer cell migration and invasion, and its inhibitors are potential anticancer drugs. In developmental biology, MRCK is involved in embryonic gastrulation and the establishment of epithelial cell polarity, and its abnormal function may lead to developmental defects; in addition, the specific expression of MRCKγ in muscle tissue suggests that it may be associated with the pathological mechanism of muscle-related diseases such as myotonic dystrophy, but its specific role still needs further study[1][2].

Cdc42-binding kinase亚型特异性产品:Cdc42-binding kinase Isoform Comparison
共 5种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
(R)-BDP9066

(R)-BDP9066 是 BDP9066 的一种异构体,其活性弱于 BDP9066,而 BDP9066 是强直性肌营养不良激酶相关 Cdc42 结合激酶 (MRCK) 的有效抑制剂,(R)-BDP9066 来自专利 WO2019034890A1 (E118)。

2284549-25-1
Inhibitor
98.49%
(R)-BDP9066
BDP8900

BDP8900 是一种强效且选择性的肌强直性营养不良相关 Cdc42 结合激酶(MRCKα 和 MRCKβ)抑制剂,可降低底物磷酸化,从而导致癌细胞发生形态变化、运动抑制和侵袭性降低。

2226507-05-5
Inhibitor
BDP8900
BDP9066

BDP9066 是一种针对肌强直性肌营养不良相关 Cdc-42 结合激酶 MRCK 的选择性有效抑制剂,在 SCC12 细胞中测得其对 MRCKβ 的 IC50 值为 64 nM,对 MRCKα/β 的 Ki 值分别为 0.0136 nM 和 0.0233 nM,可用于皮肤癌研究。

2226507-04-4
Inhibitor
98.18%
BDP9066
DJ4

DJ4 是一种 ATP 竞争性 ROCK1/2(IC50 值:5 和 50 nM)和 MRCKα/β(IC50 值:10 和 100 nM)抑制剂,可阻断应力纤维形成并抑制癌细胞迁移和侵袭,可用于研究肺癌、乳腺癌和胰腺癌 (PANC-1)。

1681020-24-5
Inhibitor
99.25%
DJ4
Rac/Cdc42-IN-1

Rac/Cdc42-IN-1 是口服 Rac/Cdc42 抑制剂 MBQ-167 (MS-G73758) 的体内主要 I 相代谢产物,也是一种选择性 Rac 抑制剂,通过阻断 Rac1 的 GTP 结合活化发挥作用,靶向下游 PAK1/2/3 的 Thr423/Thr402/Thr436 和 Ser141/Ser144/Ser154 自磷酸化,且抑制效果优于 MBQ-167,能显著抑制细胞迁移,并在 HER2 + 乳腺癌小鼠模型中抑制肿瘤生长及肺、肝、肾远端转移,因此可用于转移性乳腺癌的靶向研究。

2143950-05-2
Inhibitor
Rac/Cdc42-IN-1

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础